The company’s lead asset, CTX-712, is in phase 1 clinical trials for advanced, relapsed or refractory malignant cancers. It is an orally available, selective, small-molecule inhibitor of CDC ...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage trial ...